97 related articles for article (PubMed ID: 21711375)
1. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
[TBL] [Abstract][Full Text] [Related]
2. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
Colombo-Benkmann M; Li Z; Riemann B; Hengst K; Herbst H; Keuser R; Gross U; Rondot S; Raue F; Senninger N; Pützer BM; Frank-Raue K
Eur J Endocrinol; 2008 Jun; 158(6):811-6. PubMed ID: 18322301
[TBL] [Abstract][Full Text] [Related]
5. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
6. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
Cosci B; Vivaldi A; Romei C; Gemignani F; Landi S; Ciampi R; Tacito A; Molinaro E; Agate L; Bottici V; Cappagli V; Viola D; Piaggi P; Vitti P; Pinchera A; Elisei R
Endocr Relat Cancer; 2011 Oct; 18(5):603-12. PubMed ID: 21810974
[TBL] [Abstract][Full Text] [Related]
7. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
[TBL] [Abstract][Full Text] [Related]
8. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.
Machens A; Schneyer U; Holzhausen HJ; Raue F; Dralle H
Surgery; 2004 Nov; 136(5):1083-7. PubMed ID: 15523405
[TBL] [Abstract][Full Text] [Related]
9. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
[TBL] [Abstract][Full Text] [Related]
10. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
[TBL] [Abstract][Full Text] [Related]
12. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
[TBL] [Abstract][Full Text] [Related]
14. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
16. Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E286-92. PubMed ID: 24297798
[TBL] [Abstract][Full Text] [Related]
17. The Y606C RET mutation causes a receptor gain of function.
Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
[TBL] [Abstract][Full Text] [Related]
18. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland.
Paszko Z; Sromek M; Czetwertynska M; Skasko E; Czapczak D; Wisniewska A; Prokurat A; Chrupek M; Jagielska A; Kozlowicz-Gudzinska I
Cancer Invest; 2007 Dec; 25(8):742-9. PubMed ID: 18058472
[TBL] [Abstract][Full Text] [Related]
19. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
[TBL] [Abstract][Full Text] [Related]
20. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
